Informatie:
Fout:
ID
34413
Beschrijving
Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01753375
Link
https://clinicaltrials.gov/show/NCT01753375
Trefwoorden
Versies (1)
- 17-01-19 17-01-19 -
Houder van rechten
GSK group of companies
Geüploaded op
17 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Multiple Sclerosis NCT01753375
Eligibility Multiple Sclerosis NCT01753375
- StudyEvent: Eligibility
Similar models
Eligibility Multiple Sclerosis NCT01753375
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
age between 18-55 years
boolean
ID.2
Item
confirmed multiple sclerosis diagnosis according to mcdonald criteria
boolean
ID.3
Item
stable neurological functioning for at least one month prior to study entry
boolean
ID.4
Item
expanded disability scale score (edss) less than <_4.0
boolean
ID.5
Item
must have had one clinical attack in past two years and at least one new silent t2 or gadolinium-enhancing lesion on mri within the past one year.
boolean
ID.6
Item
willing to participate for the entire 52-week period
boolean
ID.7
Item
pregnant or nursing.
boolean
ID.8
Item
connective tissue disease (sle, sjogren's disease)
boolean
ID.9
Item
endocrine disease (hyperthyroidism, hyperparathyroidism)
boolean
ID.10
Item
any medical condition predisposing to hypercalcaemia, nephrolithiasis or renal insufficiency
boolean